1. Kaineng Health
The net profit forecast for the mid-year report is 8.73%, with an increase of 47.83% in the first half of 221; Jiyuan Meiye, a wholly-owned subsidiary of the company, is committed to innovating and developing cell-level skin repair technology. The core products use the world's leading clinical-level biological protein gene recombination and self-patented protein recombination technology, which has the field of effective anti-aging repair and beauty. The reason for the change of the company's performance is mainly because the downstream market of products has been opened, which is no longer affected by the epidemic situation, and the prosperity index of the industry has gradually recovered. In 221, the company seized all the business opportunities of consumption recovery on a global scale, and launched various new products and improved the industrial chain to achieve a substantial increase in performance.
2. Aoyuan Meigu
The net profit forecast for the mid-year report is 127.46%, with an increase of 178.3% in the first half of 221; Guangzhou Ogilvy & Mather, a wholly-owned subsidiary of the company, and KD Company * * * set up a joint venture company, and the joint venture company represented the products in China. KD was founded in Korea. From its main business, we can see that it is a high-tech company that sells medical beauty equipment and develops and researches active raw materials in beauty. The reason for the surge in performance is also the factors brought about by the merger. In the second quarter, Zhejiang Liantianmei Company was acquired. In the first half of last year, due to the epidemic situation, the production and sales of chemical fiber plate were affected to some extent.
III. Harbin Sanlian
The net profit forecast for the annual interim report is 1892.11%, with an increase of 251.58% in the first half of 221; The reason why Harbin Sanlian fits medical beauty is that it shares in Fuerjia. Most of its main products are medical beauty products, including: medical sodium hyaluronate repair patch, medical sodium hyaluronate repair solution and so on. The company holds 1% equity of Beixing Pharmaceutical Co., Ltd. for foreign investment. The reason for the pre-increase in the semi-annual report is mainly due to the impact of non-recurring profit and loss. The company confirmed that the impact of investment income on the profit and loss of the company's consolidated statements in 221 is about 566 million yuan.
iv. Huaxi Bio
predicted a net profit of 35.% in the annual interim report, with an increase of 12.23% in the first half of 221; As an authentic leader in the medical and beauty industry, the company is currently a core high-tech enterprise, the world's leading producer of hyaluronic acid microbial fermentation, and the industrial scale is also among the top in the world. At the same time, it is also one of the first enterprises to produce hyaluronic acid by microbial fermentation. In June last year, the company also acquired 1% equity of Fossett, and opened a production facility of hyaluronic acid series products ahead of China. The reason for the pre-increase of the company's semi-annual report is mainly due to the growth of raw materials business and medical terminal business. Its skin care business has been singing all the way in the first half of the year, bringing nearly 1% revenue growth to the company. At the same time, during the period of revenue growth, the company also increased its efforts to give strong support to the underlying technology research and development.
v. The net profit forecast of Langzi
in the interim report is 3,228.26%, with an increase of 15.52% in the first half of 221; The three major domestic medical beauty brands "Milan", "Crystal Skin" and "Gaoyisheng" are all controlled by Langzi, and they have also invested in the well-known Korean medical beauty group DMG in the international market. This year, in addition to accelerating the pace in the women's wear industry chain, it has also been continuously promoted in medical beauty, achieving steady business development, which is of great help to the company's profits.
VI. Haohaishengke
The net profit forecast for the mid-year report is 753.7%, with an increase of 192.55% in the first half of 221; The company specializes in the research, development, production and sales ability of the whole industrial chain from upstream raw materials to terminal preparations, and produces raw materials in two ways that adapt to the current trend. The change of the company's performance mainly comes from the epidemic situation. In the first half of this year, the epidemic situation has been effectively controlled, so as to carry out various market activities, expand influence and increase product demand.
VII. Teyi Pharmaceutical
The net profit forecast for the annual interim report is 18.%, with an increase of 21.% in the first half of 221; The company plans to invest 1 million yuan to set up Guangdong Temei Health Science and Technology Industry Co., Ltd., and the company to be set up is a big health industry investment and operation platform of Teyi Pharmaceutical Group, and its development direction includes fully deploying the development and investment in the field of medical beauty services. The sales volume of the company's core products has gradually increased, and the business has also returned to normal level. The company has continuously strengthened brand building, optimized product structure, increased internal management, and persisted in reducing costs and increasing efficiency, and achieved good results.
VIII. Blonde Rabbi
The net profit forecast for the mid-year report is 114.72%, with an increase of 139.51% in the first half of 221; The company has an old experience in the medical beauty industry, and has invested in Guangdong Hanfei Hospital, a medical beauty enterprise, and also holds five medical beauty institutions under the company's banner. The company's business plan was carried out in an orderly manner, and the online and offline channel layout, marketing strategy, management mode and product research and development mode were adjusted. Compared with the same period last year, the company's revenue this year has recovered to a great extent.
IX. Chengzhi Co., Ltd.
The net profit forecast for the annual interim report is 458.77%, with an increase of 24.54% in the first half of 221; Official website, a wholly-owned subsidiary of Chengzhi Life Science and Technology Co., Ltd., shows that it produces hyaluronic acid. The domestic supply and demand for medical beauty has been significantly improved after the epidemic last year. The sales of related products of the company have been greatly increased due to the reversal of raw material prices in the clean energy business. At the same time, the market demand for semiconductor liquid crystal display materials of the company has increased, and the production and sales volume have increased significantly, which has also brought about an increase in the company's profits.
X. Huilong shares
The annual interim net profit forecast is 1.%, with an increase of 35.71% in the first half of 221; Haihua technology has long been concerned about the production technology of hyaluronic acid products, and has produced related products in pilot scale. Shanghai Shaohua Biotechnology Development Co., Ltd., a subsidiary of Haihua Technology, is mainly responsible for the promotion, sales and technology research and development of the company's future medical beauty products. The company's chemical trade business adjusted its business ideas, focused on core suppliers, core customers and core products, and strengthened management and control, and its business performance increased substantially year-on-year.